C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

On July 16, 2024 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain (Press release, C4 Therapeutics, JUL 16, 2024, View Source [SID1234644887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Saturday, September 14, 2024, 2:45 – 2:50 CEST
Final Publication Number: 612MO
Session Category: Mini oral session
Session Title: Developmental therapeutics
Location: Oviedo Auditorium – Hall 3
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain, La Coruña)

4SC receives Orphan Drug Status (ODS) for resminostat (Kinselby) in cutaneous T-cell lymphoma in Switzerland

On July 16, 2024 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage CTCL, reported to have received notification from the Swiss Agency for Therapeutic Products (SwissMedic) that it has granted Orphan Drug Status to resminostat for the treatment of CTCL (Press release, 4SC, JUL 16, 2024, View Source [SID1234644874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In Switzerland, ODS provides privileged status to drugs that show promise for the treatment of rare diseases and this qualifies 4SC for benefits including fee reductions and a faster review process.

This follows previous announcements that both the European Medicines Agency and the US Food and Drug Administration had granted resminostat (Kinselby) orphan drug designation. This gives a number of benefits, most importantly ten and seven years’ market exclusivity respectively in the EU and US.

Jason Loveridge, Ph.D., CEO of 4SC, commented: "Receiving orphan drug status in Switzerland builds on the solid foundation of regulatory support that we already have in the EU and US and will help our efforts to commercialise Kinselby in these major markets."

Clarity signs supply agreement for Ac-225 with TerraPower Isotopes and launches Ac-225 bisPSMA program

On July 16, 2024 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported that it has entered into a supply agreement with TerraPower for Ac-225 for Clarity’s 225Ac-bisPSMA program (Press release, Clarity Pharmaceuticals, JUL 16, 2024, View Source [SID1234644867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, "We are very excited to explore the benefits of our proprietary optimised dual-targeted PSMA product in our first TAT program utilising TerraPower-supplied Ac-225. We have the right team to develop and later commercialise a best-in-class TAT product to complement the treatment paradigm, particularly in later-stage prostate cancer patients, and overcome the hurdles seen with other PSMA-based targeting agents.

"Manufacturing of Ac-225 poses a number of challenges at this time, including access for clinical studies, purity of isotope and scalability to meet requirements for a commercial launch. The Ac-225 from TerraPower fits into our strategy of developing sustainable, scalable and environmentally preferred solutions to radionuclide sourcing at a purity level appropriate for clinical practice and made directly in the United States. This avoids having to supply Ac-225 from Russia and use sources containing significant Ac-227 contamination, a radionuclide more radiotoxic than plutonium. A number of other isotope manufacturers are now developing potentially scalable commercial processes, including our existing partner for copper-67 supply, NorthStar Medical Isotopes LLC, and we will look to continue adding Ac-225 suppliers to our network. As such, with increasing focus on the Ac-225 supply chain, the probability of successfully developing and commercialising these treatments has grown from a supply perspective.

"The new beta-particle therapies, such as Cu-67 and Lu-177, with their favourable energy characteristics and path lengths, are revolutionising the radiopharmaceutical space because of their proven efficacy and excellent safety profiles compared to many other beta and alpha emitting isotopes. The small number of commercially available targeted radiopharmaceutical therapies all use beta emitting isotopes, and they represent the best opportunity to significantly change the treatment paradigm with the potential for much earlier stage treatments and in combination with standard of care treatments or immuno-oncology products. Novartis, the current leader in radiopharmaceuticals, has cornered much of the Lu-177 supply market, given the precarious supply chain of Lu-177 and reliance on a limited number of aging nuclear reactors, inhibiting new companies from entering this space1. Clarity’s unique proprietary position of having a cage that holds copper isotopes and exclusive supply of Cu-67, which is sourced from scalable electron accelerators as opposed to the small and aging fleet of nuclear reactors, means that Clarity is well positioned to drive a global shift in the treatment paradigm for cancer sufferers. As such, beta-particle therapy with Targeted Copper Theranostics (TCTs) remains Clarity’s key focus.

"Clarity’s bisPSMA program could be the game-changer in prostate cancer therapy given the increased uptake and retention in tumours enabled by the dual-targeting molecule and with impressive preclinical and clinical data generated to date. By combining our optimised bisPSMA with Ac-225, we have the opportunity to complement our beta-particle therapy product, 67Cu-SAR-bisPSMA. Developing both alpha- and beta-emitting therapy products for prostate cancer puts Clarity in a unique position to offer powerful treatment approaches to improve outcomes for these patients as using each product at different stages of the disease would provide more options to the patients.

"Our 225Ac-bisPSMA preclinical research program has been underway for some months with investigations to date focused on identifying a lead compound from a number of different analogues through measuring biodistribution, tumour uptake, radiolabelling efficiency and product stability as we move closer to clinical development with an optimised PSMA agent utilising Ac-225.

"By integrating TAT into our existing advanced TCT programs, Clarity is positioning itself to fundamentally transform the arsenal of treatments available for oncologists and their patients. This strategic move allows us to broaden our deep pipeline of clinical and pre-clinical assets and make significant progress towards our ultimate goal of better treating adults and children with cancer."

The Supply Agreement is effective July 2024. Supply under this agreement is expected to commence in November 2024, while supply before November 2024 will be carried out under the existing Limited Product Supply and Evaluation Agreement. The supply agreement is for an initial period of 2 years and can be extended under the terms of the contract. Cancellation provisions are at industry standard rates.

Entry into a Material Definitive Agreement

On July 15, 2024, Pulse Biosciences, Inc. (the "Company") reported to have entered into an equity distribution agreement (the "Distribution Agreement") with Canaccord Genuity LLC and Needham & Company, LLC (each a "Sales Agent" and together, the "Sales Agents"), as sales agents, pursuant to which the Company may offer and sell, from time to time, through the Sales Agents, shares of the Company’s common stock, par value $0.001 per share (the "Common Stock"), having an aggregate offering price of up to $60.0 million (the "Shares") (Filing, Pulse Biosciences, JUL 15, 2024, View Source [SID1234644892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is not obligated to sell any Shares under the Distribution Agreement. Subject to the terms and conditions of the Distribution Agreement, the Sales Agents will use commercially reasonable efforts, consistent with their normal trading and sales practices, to sell Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions specified by the Company. Under the Distribution Agreement, the Sales Agents may sell Shares in transactions that are deemed to be "at the market" offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"), including sales made by means of ordinary brokers’ transactions, including directly on the Nasdaq Capital Market or into any other existing trading market for the Shares, or sales made to or through a market maker, in block transactions or by any other method permitted by law, including negotiated transactions. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices or at negotiated prices. The Company will pay the Sales Agents a commission of up to 3.0% of the gross sales price per share sold by the Sales Agents. The Company also will reimburse the Sales Agents for certain specified expenses in connection with entering into the Distribution Agreement. The Company has no obligation to sell any of the Shares under the Distribution Agreement and may at any time suspend solicitations and offers under the Distribution Agreement.

The issuance and sale, if any, of the Shares by the Company under the Distribution Agreement will be made pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-278322) filed with the U.S. Securities and Exchange Commission (the "SEC") on March 28, 2024, and declared effective as of April 8, 2024, as well as a related registration statement on Form S-3 (File No. 333-280805), filed with the SEC on July 15, 2024 pursuant to Rule 462(b) of the Securities Act, which became effective immediately upon filing. The Company filed a prospectus supplement with the SEC on July 15, 2024 in connection with the offer and sale of the Shares pursuant to the Distribution Agreement.

The foregoing description of the Distribution Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Distribution Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The legal opinion of Baker & Hostetler LLP, counsel to the Company, relating to the validity of the issuance and sale of the Shares being offered pursuant to the Distribution Agreement, is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Distribution Agreement nor shall there be any sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Diakonos Oncology Receives FDA Fast Track Designation for Pancreatic Cancer Dendritic Cell Vaccine; Names Daniel D. Von Hoff, M.D. to Scientific Advisory Board

On July 15, 2024 Diakonos Oncology Corporation ("Diakonos"), a clinical stage immuno-oncology company, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s unique dendritic cell vaccine (DCV) for pancreatic ductal adenocarcinoma (Press release, Diakonos Oncology, JUL 15, 2024, View Source [SID1234644881]). In addition, the company has named to its Scientific Advisory Board, Daniel D. Von Hoff, M.D., Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, AZ, and City of Hope, and an experienced investigator against pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This second FDA Fast Track designation of our autologous dendritic cell vaccines for pancreatic cancer is another acknowledgement of the incredible potential of this innovative immunotherapy for treating the most deadly cancers," said Mike Wicks, Diakonos CEO. "We are thrilled to have Dr. Von Hoff join us as an advisor as we pursue clinical development of our vaccine in this deadly disease," Mr. Wicks added. "The first designation was for our lead vaccine for glioblastoma multiforme (GBM) which successfully completed dosing for the Phase 1 trial and has significantly improved 12 month survival in those patients to well over what would be expected with the standard of care." (See the press release)

Dr. Von Hoff is an internationally recognized physician and scientist whose research has contributed to the development of many anticancer agents that are routinely used in clinical practice. His research at TGEN focuses on development of therapies for patients with advanced pancreatic cancer. He also was a founder of ILEX Oncology which was acquired by Genzyme.

In addition to his work with TGEN, Dr. Von Hoff holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute, and is Professor of Medicine at the Mayo Clinic, Scottsdale, AZ.

"Diakonos’s unique dendritic cell vaccine has shown encouraging results in treating glioblastoma, a terrible disease with few effective treatments. Pancreatic cancer patients also need additional treatment options," said Dr. Von Hoff. "I look forward to working with Diakonos to help develop effective treatments for patients with pancreatic cancer with the same targeted technology."

About FDA Fast Track:

FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions. Pancreatic ductal adenocarcinoma is the most common pancreatic cancer. It is the third leading cause of cancer deaths in the U.S. and the number of cases is growing. According to the National Institutes of Health, the average five-year survival rate is less than 13%, and in 2024 an estimated 51,750 people will die and 66,440 will be newly diagnosed.

About Diakonos’ DCV Technology:

The company’s DCVs are made with a patient’s dendritic cells and a sample of their tumor. These highly differentiated double-loaded dendritic cell vaccines activate robust cytotoxic TH1 cell signaling pathways that initiate a natural immune response to target and eliminate cancer cells. This is achieved without any genetic modification of the patient’s immune cells, which greatly simplifies the manufacturing process and significantly reduces costs when compared to leading cell therapy approaches.